(Partial) loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes

Vito Chiantera, Sylvia Mechsner, Vito Chiantera, Abrão, Christhardt Köhler, Darb-Esfahani, Eliane T. Taube, Borrelli

Risultato della ricerca: Article

9 Citazioni (Scopus)

Abstract

study hypothesis: Loss of protein BAF250a (ARID1A) expression is present in women with rectovaginal deep-infiltrating endometriosis (DIE) and endometriosis affecting the pelvic sentinel lymph nodes (PSLN). study finding: Partial loss of protein BAF250a was found in some of our patient samples, comprising all endometriosis entities, including rectovaginal DIE and endometriosis affecting the PSLN. what is known already: Loss of BAF250a (BRG-associated factor 250a)/ARIDIA (AT-rich interactive domain 1A) protein expression was identified among endometriosis-associated ovarian carcinomas and ovarian endometriosis, and this phenomenonwas described as a possible early event in the transformation of endometriosis into cancer. DIE affecting the bowel/rectovaginal site is the most aggressive presentation of endometriosis and its 'risk' of malignant transformation has not been studied so far. study design, samples/materials, methods: We evaluated the immunohistochemical expression of BAF250a protein in 70 samples from patients enrolled in this study who were surgically treated at a tertiary center, university Hospital. The samples submitted to investigation were from rectovaginal DIE (n 1/4 25/30), endometriosis affecting the PSLN (n 1/4 5/7), ovarian endometriosis (n 1/4 20/20) and endometrium from patients without endometriosis used as controls (n 1/4 20/20). main results and the role of chance: Partial loss (i.e. in one tissue section some cells stained positive for BAF250a while other cells, usually an adjacent group, were negative) of BAF250a protein was identified in 36% (9/25) of rectovaginal DIE samples, 40% (2/5) of endometriosis lesions involving the PSLN, 30% (6/20) of endometriomas, and also in 25% (5/20) of endometrium from controls. We found no statistical correlation between occurrence of partial loss of BAF250a protein and the use or not of hormone medications (P 1/4 0.106), cycle phase (P 1/4 0.917) and stage of disease (P 1/4 0.717). limitations, reasons for caution: We only found partial loss of BAF250a protein expression, and in a small population of women, with relatively high frequency in all benign tissues assessed in the present analysis. Therefore, this finding alone should not be correlated directly with the risk of malignant transformation in these lesions. wider implications of the findings: The occurrence of partial loss of BAF250a protein expression in women with rectovaginal DIE and endometriosis affecting the PSLN is described for the first time. The value of this finding as a predictor of malignant transformation in endometriosis must still be clarified and further studied in association with other molecular events, such as PTEN (phosphatase and tensin homolog) deletion and PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) mutation.We might then be able to identify in the future which patients with endometriosis are at higher risk of cancer. study funding and competing interest(s): This study was supported by an internal Charité grant to the Endometriosis Research Center and the authors declare no conflicts of interest.
Lingua originaleEnglish
pagine (da-a)329-337
Numero di pagine9
RivistaMolecular Human Reproduction
Volume22
Stato di pubblicazionePublished - 2016

Fingerprint

Endometriosis
Sentinel Lymph Node
Proteins
Endometrium
Conflict of Interest

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Cell Biology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Genetics
  • Molecular Biology
  • Embryology

Cita questo

(Partial) loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes. / Chiantera, Vito; Mechsner, Sylvia; Chiantera, Vito; Abrão; Köhler, Christhardt; Darb-Esfahani; Taube, Eliane T.; Borrelli.

In: Molecular Human Reproduction, Vol. 22, 2016, pag. 329-337.

Risultato della ricerca: Article

Chiantera, V, Mechsner, S, Chiantera, V, Abrão, Köhler, C, Darb-Esfahani, Taube, ET & Borrelli 2016, '(Partial) loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes', Molecular Human Reproduction, vol. 22, pagg. 329-337.
Chiantera, Vito ; Mechsner, Sylvia ; Chiantera, Vito ; Abrão ; Köhler, Christhardt ; Darb-Esfahani ; Taube, Eliane T. ; Borrelli. / (Partial) loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes. In: Molecular Human Reproduction. 2016 ; Vol. 22. pagg. 329-337.
@article{67149d13bd7340eb93f69468450e9093,
title = "(Partial) loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes",
abstract = "study hypothesis: Loss of protein BAF250a (ARID1A) expression is present in women with rectovaginal deep-infiltrating endometriosis (DIE) and endometriosis affecting the pelvic sentinel lymph nodes (PSLN). study finding: Partial loss of protein BAF250a was found in some of our patient samples, comprising all endometriosis entities, including rectovaginal DIE and endometriosis affecting the PSLN. what is known already: Loss of BAF250a (BRG-associated factor 250a)/ARIDIA (AT-rich interactive domain 1A) protein expression was identified among endometriosis-associated ovarian carcinomas and ovarian endometriosis, and this phenomenonwas described as a possible early event in the transformation of endometriosis into cancer. DIE affecting the bowel/rectovaginal site is the most aggressive presentation of endometriosis and its 'risk' of malignant transformation has not been studied so far. study design, samples/materials, methods: We evaluated the immunohistochemical expression of BAF250a protein in 70 samples from patients enrolled in this study who were surgically treated at a tertiary center, university Hospital. The samples submitted to investigation were from rectovaginal DIE (n 1/4 25/30), endometriosis affecting the PSLN (n 1/4 5/7), ovarian endometriosis (n 1/4 20/20) and endometrium from patients without endometriosis used as controls (n 1/4 20/20). main results and the role of chance: Partial loss (i.e. in one tissue section some cells stained positive for BAF250a while other cells, usually an adjacent group, were negative) of BAF250a protein was identified in 36{\%} (9/25) of rectovaginal DIE samples, 40{\%} (2/5) of endometriosis lesions involving the PSLN, 30{\%} (6/20) of endometriomas, and also in 25{\%} (5/20) of endometrium from controls. We found no statistical correlation between occurrence of partial loss of BAF250a protein and the use or not of hormone medications (P 1/4 0.106), cycle phase (P 1/4 0.917) and stage of disease (P 1/4 0.717). limitations, reasons for caution: We only found partial loss of BAF250a protein expression, and in a small population of women, with relatively high frequency in all benign tissues assessed in the present analysis. Therefore, this finding alone should not be correlated directly with the risk of malignant transformation in these lesions. wider implications of the findings: The occurrence of partial loss of BAF250a protein expression in women with rectovaginal DIE and endometriosis affecting the PSLN is described for the first time. The value of this finding as a predictor of malignant transformation in endometriosis must still be clarified and further studied in association with other molecular events, such as PTEN (phosphatase and tensin homolog) deletion and PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) mutation.We might then be able to identify in the future which patients with endometriosis are at higher risk of cancer. study funding and competing interest(s): This study was supported by an internal Charit{\'e} grant to the Endometriosis Research Center and the authors declare no conflicts of interest.",
author = "Vito Chiantera and Sylvia Mechsner and Vito Chiantera and Abr{\~a}o and Christhardt K{\"o}hler and Darb-Esfahani and Taube, {Eliane T.} and Borrelli",
year = "2016",
language = "English",
volume = "22",
pages = "329--337",
journal = "Molecular Human Reproduction",
issn = "1360-9947",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - (Partial) loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes

AU - Chiantera, Vito

AU - Mechsner, Sylvia

AU - Chiantera, Vito

AU - Abrão, null

AU - Köhler, Christhardt

AU - Darb-Esfahani, null

AU - Taube, Eliane T.

AU - Borrelli, null

PY - 2016

Y1 - 2016

N2 - study hypothesis: Loss of protein BAF250a (ARID1A) expression is present in women with rectovaginal deep-infiltrating endometriosis (DIE) and endometriosis affecting the pelvic sentinel lymph nodes (PSLN). study finding: Partial loss of protein BAF250a was found in some of our patient samples, comprising all endometriosis entities, including rectovaginal DIE and endometriosis affecting the PSLN. what is known already: Loss of BAF250a (BRG-associated factor 250a)/ARIDIA (AT-rich interactive domain 1A) protein expression was identified among endometriosis-associated ovarian carcinomas and ovarian endometriosis, and this phenomenonwas described as a possible early event in the transformation of endometriosis into cancer. DIE affecting the bowel/rectovaginal site is the most aggressive presentation of endometriosis and its 'risk' of malignant transformation has not been studied so far. study design, samples/materials, methods: We evaluated the immunohistochemical expression of BAF250a protein in 70 samples from patients enrolled in this study who were surgically treated at a tertiary center, university Hospital. The samples submitted to investigation were from rectovaginal DIE (n 1/4 25/30), endometriosis affecting the PSLN (n 1/4 5/7), ovarian endometriosis (n 1/4 20/20) and endometrium from patients without endometriosis used as controls (n 1/4 20/20). main results and the role of chance: Partial loss (i.e. in one tissue section some cells stained positive for BAF250a while other cells, usually an adjacent group, were negative) of BAF250a protein was identified in 36% (9/25) of rectovaginal DIE samples, 40% (2/5) of endometriosis lesions involving the PSLN, 30% (6/20) of endometriomas, and also in 25% (5/20) of endometrium from controls. We found no statistical correlation between occurrence of partial loss of BAF250a protein and the use or not of hormone medications (P 1/4 0.106), cycle phase (P 1/4 0.917) and stage of disease (P 1/4 0.717). limitations, reasons for caution: We only found partial loss of BAF250a protein expression, and in a small population of women, with relatively high frequency in all benign tissues assessed in the present analysis. Therefore, this finding alone should not be correlated directly with the risk of malignant transformation in these lesions. wider implications of the findings: The occurrence of partial loss of BAF250a protein expression in women with rectovaginal DIE and endometriosis affecting the PSLN is described for the first time. The value of this finding as a predictor of malignant transformation in endometriosis must still be clarified and further studied in association with other molecular events, such as PTEN (phosphatase and tensin homolog) deletion and PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) mutation.We might then be able to identify in the future which patients with endometriosis are at higher risk of cancer. study funding and competing interest(s): This study was supported by an internal Charité grant to the Endometriosis Research Center and the authors declare no conflicts of interest.

AB - study hypothesis: Loss of protein BAF250a (ARID1A) expression is present in women with rectovaginal deep-infiltrating endometriosis (DIE) and endometriosis affecting the pelvic sentinel lymph nodes (PSLN). study finding: Partial loss of protein BAF250a was found in some of our patient samples, comprising all endometriosis entities, including rectovaginal DIE and endometriosis affecting the PSLN. what is known already: Loss of BAF250a (BRG-associated factor 250a)/ARIDIA (AT-rich interactive domain 1A) protein expression was identified among endometriosis-associated ovarian carcinomas and ovarian endometriosis, and this phenomenonwas described as a possible early event in the transformation of endometriosis into cancer. DIE affecting the bowel/rectovaginal site is the most aggressive presentation of endometriosis and its 'risk' of malignant transformation has not been studied so far. study design, samples/materials, methods: We evaluated the immunohistochemical expression of BAF250a protein in 70 samples from patients enrolled in this study who were surgically treated at a tertiary center, university Hospital. The samples submitted to investigation were from rectovaginal DIE (n 1/4 25/30), endometriosis affecting the PSLN (n 1/4 5/7), ovarian endometriosis (n 1/4 20/20) and endometrium from patients without endometriosis used as controls (n 1/4 20/20). main results and the role of chance: Partial loss (i.e. in one tissue section some cells stained positive for BAF250a while other cells, usually an adjacent group, were negative) of BAF250a protein was identified in 36% (9/25) of rectovaginal DIE samples, 40% (2/5) of endometriosis lesions involving the PSLN, 30% (6/20) of endometriomas, and also in 25% (5/20) of endometrium from controls. We found no statistical correlation between occurrence of partial loss of BAF250a protein and the use or not of hormone medications (P 1/4 0.106), cycle phase (P 1/4 0.917) and stage of disease (P 1/4 0.717). limitations, reasons for caution: We only found partial loss of BAF250a protein expression, and in a small population of women, with relatively high frequency in all benign tissues assessed in the present analysis. Therefore, this finding alone should not be correlated directly with the risk of malignant transformation in these lesions. wider implications of the findings: The occurrence of partial loss of BAF250a protein expression in women with rectovaginal DIE and endometriosis affecting the PSLN is described for the first time. The value of this finding as a predictor of malignant transformation in endometriosis must still be clarified and further studied in association with other molecular events, such as PTEN (phosphatase and tensin homolog) deletion and PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) mutation.We might then be able to identify in the future which patients with endometriosis are at higher risk of cancer. study funding and competing interest(s): This study was supported by an internal Charité grant to the Endometriosis Research Center and the authors declare no conflicts of interest.

UR - http://hdl.handle.net/10447/179418

UR - http://molehr.oxfordjournals.org/

M3 - Article

VL - 22

SP - 329

EP - 337

JO - Molecular Human Reproduction

JF - Molecular Human Reproduction

SN - 1360-9947

ER -